查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1566764

脊椎生技藥品市場：按產品、最終用戶：2024-2033 年全球機會分析與產業預測

Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

脊椎生技藥品市場

2023年脊椎生技藥品市值為30.5億美元，預計2035年將達55.5億美元，2024年至2035年複合年成長率為5.29%。

脊椎生技藥品由促進脊椎融合、促進癒合和治療多種脊椎疾病的材料組成。這種材料含有生長因子、幹細胞和骨移植物，有助於身體的自然癒合過程。骨移植是新骨生長所需的支架。骨移植包括來自患者自身的自體移植物和來自捐贈者的異體移植物。幹細胞是能夠產生具有完整功能的新細胞的特殊細胞，骨生成激素（BMP）等生長因子在刺激細胞再生和骨骼修復方面發揮作用。脊椎生技藥品在連接兩個或更多脊椎骨的脊椎融合手術中廣泛使用。

脊椎疾病的盛行率不斷增加，特別是在快速成長的老年人口中，是脊椎生技藥品市場的主要促進因素。此外，隨著微創手術趨勢的日益發展，對在脊椎手術過程中最大限度地減少侵入性並促進癒合的脊椎生技藥品的需求激增。近年來，利用積層製造開發移植骨替代物已成為市場的新興趨勢。與骨移植物相比，這些替代品具有相當的功效和更高的安全性，骨移植物有可能被生物體排斥。

然而，脊椎生技藥品的開發過程複雜且成本高昂，限制了市場的發展。此外，無效的報銷政策導致脊椎手術保險不足，阻礙了昂貴的治療並限制了市場成長。相反，脊椎損傷的數量不斷增加，預計未來將推動脊椎生技藥品的需求。美國國家醫學圖書館最近發表的一篇論文顯示，美國每年新發脊髓損傷的38%是由於機動車事故造成的，而跌倒是脊髓損傷的第二常見原因，佔30%。的%。

按部門審查

脊椎生技藥品市場分為產品、最終用戶和地區。根據產品，它分為脊椎同種異體移植物、移植骨替代物和基於細胞的基質。依最終使用者分為醫院和門診設施。從區域來看，分析包括北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

從產品來看，脊椎植入物細分市場將在 2023 年佔據主導地位。

按最終用戶分類，醫院細分市場在 2023 年將佔據較高市場佔有率。

按地區分類，預計到 2035 年，北美地區的收益將最高。

該報告可以客製化。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 歷史市場資料
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章脊椎生技藥品市場：依產品

  • 市場概況
  • 脊椎移植物
  • 移植骨替代物
  • 基於細胞的矩陣

第5章脊椎生技藥品市場：依最終用戶分類

  • 市場概況
  • 醫院
  • 門診病人設施

第6章脊椎生技藥品市場：依地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國脊椎生技藥品市場
    • 加拿大脊椎生技藥品市場
    • 墨西哥脊椎生技藥品市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國脊椎生技藥品市場
    • 法國脊椎生技藥品市場
    • 英國脊椎生技藥品市場
    • 義大利脊椎生技藥品市場
    • 西班牙脊椎生技藥品市場
    • 其他歐洲脊椎生技藥品市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本脊椎生技藥品市場
    • 中國脊椎生技藥品市場
    • 澳洲脊椎生技藥品市場
    • 印度脊椎生技藥品市場
    • 韓國脊椎生技藥品市場
    • 其他亞太脊椎生技藥品市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西脊椎生技藥品市場
    • 沙烏地阿拉伯脊椎生技藥品市場
    • 南非脊椎生技藥品市場
    • 其他拉丁美洲/中東/非洲脊椎生技藥品市場

第7章 競爭狀況

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 競爭對手儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • Stryker Corporation
  • NuVasive, Inc.
  • Orthofix
  • Johnson And Johnson
  • Exactech, Inc
  • Zimmer Biomet Holding, Inc.
  • Arthrex, Inc.
  • Medtronic Plc
  • Organogenesis Inc
  • Kuros Biosciences
簡介目錄
Product Code: A01625

Spine Biologics Market

The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.

Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.

Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.

However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.

Segment Review

The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By product, the spinal allografts segment dominated the market in 2023.

As per end user, the hospital segment acquired a high stake in the market in 2023.

Region wise, North America is projected to be the highest revenue generator by 2035.

Competition Analysis

The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product

  • Spinal Allografts
  • Bone Graft Substitutes
  • Cell-Based Matrix

By End User

  • Hospitals
  • Outpatient Facilities

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Stryker Corporation
    • NuVasive, Inc.
    • orthofix
    • Johnson & Johnson
    • Exactech, Inc
    • Zimmer Biomet Holding, Inc.
    • Arthrex, Inc.
    • Medtronic plc
    • Organogenesis Inc
    • Kuros Biosciences

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Product
  • 4.2. Spinal Allografts
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Bone Graft Substitutes
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
  • 4.4. Cell-Based Matrix
    • 4.4.1. Key Market Trends, Growth Factors and Opportunities
    • 4.4.2. Market Size and Forecast, By Region
    • 4.4.3. Market Share Analysis, By Country

CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By End User
  • 5.2. Hospitals
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Outpatient Facilities
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Product
    • 6.2.3. Market Size and Forecast, By End User
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Spine Biologics Market
      • 6.2.5.1. Market Size and Forecast, By Product
      • 6.2.5.2. Market Size and Forecast, By End User
    • 6.2.6. Canada Spine Biologics Market
      • 6.2.6.1. Market Size and Forecast, By Product
      • 6.2.6.2. Market Size and Forecast, By End User
    • 6.2.7. Mexico Spine Biologics Market
      • 6.2.7.1. Market Size and Forecast, By Product
      • 6.2.7.2. Market Size and Forecast, By End User
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Product
    • 6.3.3. Market Size and Forecast, By End User
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Spine Biologics Market
      • 6.3.5.1. Market Size and Forecast, By Product
      • 6.3.5.2. Market Size and Forecast, By End User
    • 6.3.6. France Spine Biologics Market
      • 6.3.6.1. Market Size and Forecast, By Product
      • 6.3.6.2. Market Size and Forecast, By End User
    • 6.3.7. UK Spine Biologics Market
      • 6.3.7.1. Market Size and Forecast, By Product
      • 6.3.7.2. Market Size and Forecast, By End User
    • 6.3.8. Italy Spine Biologics Market
      • 6.3.8.1. Market Size and Forecast, By Product
      • 6.3.8.2. Market Size and Forecast, By End User
    • 6.3.9. Spain Spine Biologics Market
      • 6.3.9.1. Market Size and Forecast, By Product
      • 6.3.9.2. Market Size and Forecast, By End User
    • 6.3.10. Rest of Europe Spine Biologics Market
      • 6.3.10.1. Market Size and Forecast, By Product
      • 6.3.10.2. Market Size and Forecast, By End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Product
    • 6.4.3. Market Size and Forecast, By End User
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Spine Biologics Market
      • 6.4.5.1. Market Size and Forecast, By Product
      • 6.4.5.2. Market Size and Forecast, By End User
    • 6.4.6. China Spine Biologics Market
      • 6.4.6.1. Market Size and Forecast, By Product
      • 6.4.6.2. Market Size and Forecast, By End User
    • 6.4.7. Australia Spine Biologics Market
      • 6.4.7.1. Market Size and Forecast, By Product
      • 6.4.7.2. Market Size and Forecast, By End User
    • 6.4.8. India Spine Biologics Market
      • 6.4.8.1. Market Size and Forecast, By Product
      • 6.4.8.2. Market Size and Forecast, By End User
    • 6.4.9. South Korea Spine Biologics Market
      • 6.4.9.1. Market Size and Forecast, By Product
      • 6.4.9.2. Market Size and Forecast, By End User
    • 6.4.10. Rest of Asia-Pacific Spine Biologics Market
      • 6.4.10.1. Market Size and Forecast, By Product
      • 6.4.10.2. Market Size and Forecast, By End User
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Product
    • 6.5.3. Market Size and Forecast, By End User
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Spine Biologics Market
      • 6.5.5.1. Market Size and Forecast, By Product
      • 6.5.5.2. Market Size and Forecast, By End User
    • 6.5.6. Saudi Arabia Spine Biologics Market
      • 6.5.6.1. Market Size and Forecast, By Product
      • 6.5.6.2. Market Size and Forecast, By End User
    • 6.5.7. South Africa Spine Biologics Market
      • 6.5.7.1. Market Size and Forecast, By Product
      • 6.5.7.2. Market Size and Forecast, By End User
    • 6.5.8. Rest of LAMEA Spine Biologics Market
      • 6.5.8.1. Market Size and Forecast, By Product
      • 6.5.8.2. Market Size and Forecast, By End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Stryker Corporation
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. NuVasive, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Orthofix
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Johnson And Johnson
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Exactech, Inc
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Zimmer Biomet Holding, Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Arthrex, Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Medtronic Plc
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Organogenesis Inc
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Kuros Biosciences
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments